In a candid conversation, Chris Buyse talks about moving on from ThromboGenics – a biotech that managed to discover and develop a new drug, and get it approved and licensed, only to fall at the final hurdle of doctor and patient uptake – and leading a venture capital fund. He speaks about guiding investments during the COVID-19 pandemic and plans to double the size of the fund.
Buyse, an economist by training, found his way into the life sciences sector about 15 years ago. Around 2006, Désiré...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?